Not a good buy right now: price is extended/overbought short-term (RSI ~73) and sitting just below key resistance (R1 ~6.44) with no fresh news catalyst.
Bullish trend is intact (stacked moving averages + expanding MACD), but the near-term statistical pattern provided leans bearish over 1W–1M (expected drift lower).
With an impatient approach (unwilling to wait for a better entry), the risk/reward at 6.25 is unfavorable; best stance is to stay on the sidelines unless it breaks and holds above ~6.44–6.88 with strength.
Overbought/extension: RSI_6 at ~73 suggests short-term overheated conditions (pullback risk increases at these levels).
Key levels: Pivot 5.728; Support S1 5.014 (then 4.572); Resistance R1 6.442 (then R2 6.884). At 6.25 pre-market, price is close to R1, limiting immediate upside before resistance.
Pattern outlook (provided): 30% chance to -1.4% next day, -1.08% next week, -5.34% next month (tilts against chasing here).
Wall Street-style cons: target cut (even if minor) plus the business remains pre-revenue and outcome-driven, making timing/entry point especially important—currently not favorable for an impatient buyer.
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 27.33 USD with a low forecast of 8 USD and a high forecast of 58 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 27.33 USD with a low forecast of 8 USD and a high forecast of 58 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.490
Low
8
Averages
27.33
High
58
Current: 6.490
Low
8
Averages
27.33
High
58
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$17 -> $16
AI Analysis
2025-11-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$17 -> $16
AI Analysis
2025-11-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.
Roth Capital
NULL
to
Buy
upgrade
$10 -> $17
2025-10-14
Reason
Roth Capital
Price Target
$10 -> $17
2025-10-14
upgrade
NULL
to
Buy
Reason
Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CING
